Their research suggests that KED may support fibroblast differentiation, endothelial renewal, vascular signaling, neuronal differentiation, synaptic structure, and neuroplasticity.
Researchers also posit that it may help stressed or aging cells behave less like damaged old cells and more like cells that retain their specialized function.
Research
KED Actions on Cellular Differentiation
One of the earliest publications by the team of Khavinson et al. on KED from 2012 suggests that the peptide may interact with cellular differentiation, potentially by stimulating the expression of CXCL12 and WEDC1 in prostatic fibroblasts.(1) The authors consider these proteins as markers tied to differentiation, so they posit that KED may push aging cells and fibroblasts toward a more maintained, specialized state instead of the loss of function that develops with repeated passaging.
Based on the observations of the authors, the potential of the peptide depended strongly on cellular age. In young fibroblast cultures, the increase in cellular markers appeared to be modest: about 1.2-fold for CXCL12 and 1.5-fold for WEDC1. In mature cultures, both indicators apparently rose about 8-fold. In aged cell cultures, CXCL12 apparently rose about 7.6-fold and WEDC1 about 16-fold.
That pattern led the authors to posit that KED may act much more strongly when the cells have already undergone cellular age-related decline. Overall, the authors also posited that the peptide may possess an epigenetic mechanism via which it may support the aforementioned differentiation indicators, but more research is needed to establish the exact mechanism.
KED on Endothelial Cells
A later study by Khavinson et al. suggests that KED may increase the proliferative activity of vascular endothelial cells, especially aged cells, by targeting a gene called MKI67, which encodes the proliferation marker Ki-67.(2) The researchers posit that Ki-67 endogenously decreases during the aging process of vascular cells, but when KED was added, Ki-67 expression increased dramatically. Specifically, it increased by 1.25-fold in young cells and by 1.97-fold in old cells. The cellular explants also appeared to grow more, with area index rising by about 19% in young vascular tissue and 20% in old tissue.
Thus, the researchers posited that KED may stimulate endothelial cell growth and proliferation, with a stronger potential in aged vascular cells than in young ones. The researchers also posited that KED may help counter the cellular age-related decline in endothelial renewal, and this decline also theoretically contributes to impaired endothelial integrity and vascular dysfunction.
The authors used molecular docking to suggest that KED may bind promoter regions of the MKI67 gene, especially a sequence within the core promoter near the transcription start site. Their idea is that this binding may increase MKI67 transcription, which would then raise Ki-67 protein expression, and KED may stimulate proliferation in vascular endothelial cells, particularly old ones, and may partly restore cellular age-weakened endothelial renewal.
According to further research on endothelial cells by Kozlov et al., it appears that the “peptide has normalized endothelin-1 expression,…connexin expression…[and]….sirtuin1 expression.”(3) These observations suggest that the peptide may help bring vascular tone signaling back toward a healthier range, and may support cell-to-cell communication within the vascular wall.
KED Actions on Aging Nerve Cells
Another research by the team of Khavinson et al. from 2021 has apparently observed that KED may have an array of actions on nerve cells, including an apparent reduction in signals as cells age, an increase in neural differentiation markers, and support of gene-expression patterns linked to synaptic maintenance and neuronal survival.(4)
For example, the research has suggested that the peptide may upregulate nestin and GAP43 levels by about 1.8 to 2 times. For context, these are proteins linked to nerve cell differentiation, growth, axonal remodeling, and synaptic plasticity. This suggests KED may support neuronal differentiation or at least shift gene expression in that direction.
Moreover, the research also suggested that the peptide may suppress senescence-related brakes on the cell cycle. In an in vitro aging cellular model using stem cells, KED reportedly reduced p16 and p21 expression and protein synthesis by about 1.8 to 3.2 times.
Since p16 and p21 are classic markers and mediators of cell-cycle arrest and cellular senescence, this suggests KED may weaken the cell’s aging-associated senescence program. In other terms, it may make aged cells look less senescent at the level of these markers.
The researchers also employed aged mesenchymal stem cells and apparently observed that KED may increase SUMO1 by about 1.2 times, APOE by about 2.2 times, and IGF1 after cellular age-related decline. Consequently, they posit that KED might support pathways tied to protein handling, lipid transport, trophic support, and synaptic maintenance. Thus, KED may shift cultured cells toward a less senescent and more neurogenic expression profile, and it may support structural features of synaptic plasticity in laboratory settings.
KED Actions on Nerve Cells Function
Another 2021 publication by Khavinson et al. suggests that the KED peptide may preserve the synapses that allow for cell-to-cell communication in models of neurodegeneration.(5) Specifically, the authors commented that KED may have reduced the loss of dendritic spines, which typically form synapses to surrounding cells, in evaluations involving specific populations of hippocampal nerve cells.
More specifically, it appeared that KED may have restored mushroom spine numbers in neurodegeneration models to a level no longer different from control models. Thus, the authors hypothesized that KED may shift spine structure away from neurodegenerative patterns and toward more regular ones.
The researchers observed that the peptide may have increased total spine density by 22% and increased mushroom spines by 27%, bringing both closer to control values. KED also appeared to indicate a positive trend toward restoring LTP. According to the authors, LTP, aka long-term potentiation, “is the physiological basis of neuroplasticity, which underlies learning and memory” in similar models of nerve cell cultures.
NOTE: These products are intended for laboratory research use only. This peptide is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.
References:
- Khavinson VKh, Linkova NS, Polyakova VO, Kheifets OV, Tarnovskaya SI, Kvetnoy IM. Peptides tissue-specifically stimulate cell differentiation during their aging. Bull Exp Biol Med. 2012 May;153(1):148-51. doi: 10.1007/s10517-012-1664-1. PMID: 22808515.
- Khavinson VKh, Tarnovskaia SI, Lin’kova NS, Guton EO, Elashkina EV. [Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging]. Adv Gerontol. 2014;27(1):108-14. Russian. PMID: 25051766.
- Kozlov KL, Bolotov II, Linkova NS, Drobintseva AO, Khavinson VK, Dyakonov MM, Kozina LS. [Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis]. Adv Gerontol. 2016;29(4):646-650. Russian. PMID: 28539025.
- Khavinson VK, Lin’kova NS, Umnov RS. Peptide KED: Molecular-Genetic Aspects of Neurogenesis Regulation in Alzheimer’s Disease. Bull Exp Biol Med. 2021 May;171(2):190-193. doi: 10.1007/s10517-021-05192-6. Epub 2021 Jun 26. PMID: 34173097.
- Khavinson V, Ilina A, Kraskovskaya N, Linkova N, Kolchina N, Mironova E, Erofeev A, Petukhov M. Neuroprotective Effects of Tripeptides-Epigenetic Regulators in Mouse Model of Alzheimer’s Disease. Pharmaceuticals (Basel). 2021 May 27;14(6):515. doi: 10.3390/ph14060515. Erratum in: Pharmaceuticals (Basel). 2025 Jan 16;18(1):111. PMID: 34071923; PMCID: PMC8227791. https://doi.org/10.3390/ph18010111